Tolerance and efficacy of targeted therapies prescribed for off-label indications in refractory systemic autoimmune diseases: data of the first 100 patients enrolled in the TATA registry (TArgeted Therapy in Autoimmune Diseases)Jacques‐Eric Gottenberg, Xavier Mariette, Zahir Amoura et al.|RMD Open|2022Cited by 4
Different anti-SARS-CoV-2 vaccine response under B- and T-cell targeted therapies versus anti-cytokine therapies in patients with inflammatory arthritidesRenaud Felten, Jean-Hugues Salmon, M. Geoffroy et al.|Joint Bone Spine|2022Cited by 1